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Background: Liver kinase 1 (LKB1) is an important multi-tasking protein linked with metabolic signaling, also
controlling polarity and cytoskeletal rearrangements in diverse cell types including cancer cells. Prolactin (PRL) and
Signal transducer and activator of transcription (STAT) proteins have been associated with breast cancer progression.
The current investigation examines the effect of PRL and STAT-mediated signaling on the transcriptional regulation
of LKB1 expression in human breast cancer cells.
Methods: MDA-MB-231, MCF-7, and T47D human breast cancer cells, and CHO-K1 cells transiently expressing the
PRL receptor (long form), were treated with 100 ng/ml of PRL for 24 hours. A LKB1 promoter-luciferase construct
and its truncations were used to assess transcriptional changes in response to specific siRNAs or inhibitors targeting
Janus activated kinase 2 (JAK2), STAT3, and STAT5A. Real-time PCR and Western blotting were applied to quantify
changes in mRNA and protein levels. Electrophoretic mobility shift (EMSA) and chromatin immunoprecipitation
(ChIP) assays were used to examine STAT3 and STAT5A binding to the LKB1 promoter.
Results: Consistent with increases in mRNA, the LKB1 promoter was up-regulated by PRL in MDA-MB-231 cells, a
response that was lost upon distal promoter truncation. A putative GAS element that could provide a STAT binding
site mapped to this region, and its mutation decreased PRL-responsiveness. PRL-mediated increases in promoter
activity required signaling through STAT3 and STAT5A, also involving JAK2. Both STATs imparted basally repressive
effects in MDA-MB-231 cells. PRL increased in vivo binding of STAT3, and more definitively, STAT5A, to the LKB1
promoter region containing the GAS site. In T47D cells, PRL down-regulated LKB1 transcriptional activity, an effect
that was reversed upon culture in phenol red-free media. Interleukin 6, a cytokine activating STAT signaling in
diverse cell types, also increased LKB1 mRNA levels and promoter activity in MDA-MB-231 cells.
Conclusions: LKB1 is differentially regulated by PRL at the level of transcription in representative human breast
cancer cells. Its promoter is targeted by STAT proteins, and the cellular estrogen receptor status may affect
PRL-responsiveness. The hormonal and possibly cytokine-mediated control of LKB1 expression is particularly relevant
in aggressive breast cancer cells, potentially promoting survival under energetically unfavorable conditions.
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Prolactin (PRL) affects a range of physiological processes
to maintain homeostasis, playing important roles in
the mammary gland (reviewed in [1]) and influencing
reproduction, maternal behavior, the immune system,
osteogenesis, blood vessel development, ion transport,
and metabolism, among other diverse functions (reviewed
in [2-5]). PRL has been definitively associated with the on-
set and progression of human breast cancer by increasing
cell proliferation (reviewed in [6-8]), and may contribute
to metastasis by inducing the motility of human breast
cancer cells [9]. The human PRL receptor (PRLR) is
widely expressed in diverse tissues, and signaling through
PRLR initiates activation of several intracellular pathways,
the most well-characterized being the Janus activated kin-
ase (JAK)/signal transducer and activator of transcription
(STAT) pathway (reviewed in [3,10]). Some of the key
events that occur in the normal mammary gland during
pregnancy, lactation, and involution, as well as in adipo-
cytes and during tumorigenesis in the breast, are regulated
by STAT proteins [2-4,7,10]. The activation of cytokine
receptors, including PRLR, in response to ligand bind-
ing typically results in phosphorylation and activation
of JAK/STAT. STATs dimerize, translocate to the nucleus,
and bind to specific recognition sequences in the pro-
moter regions of select target genes, thereby activating
or repressing transcription [11,12]. Seven mammalian
STAT proteins have been identified. STAT2 is activated by
α/β interferon, STAT4 by interleukin (IL)-12, and STAT6
by IL-4 to IL-13, while STAT1, STAT3, STAT5A, and
STAT5B are activated by a range of stimuli, including PRL
and IL-6 [13,14]. Targeting Jak2 may protect against
the onset of mammary tumorigenesis in mice [15,16], and
various STAT proteins have also been associated with
breast cancer. In particular, STAT3 and STAT5 are gener-
ally thought to mediate opposite effects in mammary car-
cinoma cells [17]. Several negative regulators of JAK/STAT
signaling have been identified that are induced differently
in a cell type-dependent manner. STAT activation may
upregulate the expression of members of the Suppressors
of cytokine signalling (SOCS) family [18,19]. Other inhibi-
tors include the phosphatase SHP-1 and Protein inhibitors
of activated STAT (PIAS), which specifically targets STAT3
[20], providing another level of complexity in regulating
JAK/STAT signal transduction.
A novel mechanism by which PRL may contribute to
breast cancer progression is through its action on liver kin-
ase 1 (LKB1). Acting either as a kinase or by changing its
subcellular localization, LKB1 has been associated with pro-
liferation, cell cycle arrest, apoptosis, polarity/motility, and
energy metabolism (reviewed in [21]), and has been de-
scribed as a tumor suppressor during pulmonary tumorigen-
esis [22]. However, it has also been suggested that LKB1 is
required to protect cells from apoptosis during energy stressby initiating adenosine monophosphate-activated protein
kinase (AMPK) signaling, leading to suppression of mTOR
and the activation of ATP-producing pathways [23-25].
The LKB1-AMPK pathway has been described as a means
to rescue cancer cells from metabolic collapse [21]. We have
previously shown that PRL activates the AMPK pathway in
an LKB1-dependent manner in specific human breast cancer
cell lines, most notably MDA-MB-231 cells [26].
Little is currently known regarding how the expression of
LKB1 is regulated. One means of repression is through pro-
moter methylation [27,28], and the LKB1 promoter has
been reported to be hypermethylated in colorectal carcin-
omas and testicular tumors, although out of 51 cancer cell
lines analyzed in vitro, only one cervical carcinoma and
three colorectal cell lines were methylated at the LKB1
locus, also corresponding to loss of expression [27]. Estro-
gen may be an important regulator, as multiple estrogen re-
sponse elements (EREs) within the human LKB1 promoter
region confer a repressive action in estrogen receptor (ER)-
positive MCF-7 human breast cancer cells [29]. We have
shown previously that levels of total LKB1 mRNA and pro-
tein increase in MDA-MB-231 cells cultured in the pres-
ence of PRL [26]. Similar to PRL-responsive promoters that
contain potential STAT binding sites, such as those control-
ling expression of the β-casein [30,31], cyclin D1 [32,33],
fatty acid synthase [34], and pyruvate dehydrogenase kinase
(PDK4) genes [35], a putative STAT binding/interferon
gamma-activated sequence (GAS) motif in the distal hu-
man LKB1 promoter region was identified by computa-
tional analysis. The presence of this putative site suggested
that LKB1 transcriptional activity could be regulated by
STAT proteins. Others have shown that PRL, through
JAK2, induces binding of STAT5 to a distal GAS site in the
cyclin D1 promoter, thereby enhancing promoter activity in
Chinese hamster ovary (CHO-K1) cells transfected with the
long form (LF) of PRLR [32]. In adipocytes, STAT5A binds
to a putative STAT site in the PDK4 promoter in response
to PRL stimulation [35]. In the current investigation, we
aimed to investigate the importance of the GAS site in the
distal human LKB1 promoter region, and the potential
mechanisms underlying the responsiveness of LKB1 to
PRL, in a representative triple-negative breast cancer cell
line. Our findings demonstrate that changes in LKB1 ex-
pression are, at least in part, transcriptionally regulated by
STAT3, as well as STAT5A. Identifying the mechanisms
that underlie the regulation of LKB1 expression in different
breast cancer cells may provide new insights into how this
protein responds to different stimuli, including PRL or
other cytokines such as IL-6.
Methods
Materials
Antibodies for total LKB1, total and phospho-JAK2,
STAT3, STAT5, and ACC, and β-tubulin, β-catenin, and
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Inc, and Actin was from MP Biochemicals. The human
PRLR antibody was purchased from R&D Systems.
Individual aliquots of recombinant human PRL (Cedarlane,
Lot #608PRL01) or recombinant human IL-6 (R&D
Systems) were prepared at a concentration of 100 μg/mL
by reconstituting the lyophilates in sterile water or sterile
PBS with 0.1% BSA, respectively, and stored at −20°C. The
STAT3 pathway inhibitor (E)-3(6-bromopyridin-2-yl)-2-
cyano-N-((S0-1-phenylethyl)acrylamide) (WP1066) (Sigma),
STAT5 inhibitor (Calbiochem), and MEK1/2 inhibitor
PD098059 (NEB) were reconstituted in DMSO, individual
aliquots were stored at −20°C, and cells were pretreated
with vehicle or an appropriate working concentration for
1 hr at 37°C in 5% CO2 prior to addition of PRL for 24 hr.
Cells were pretreated with 5 μM of WP1066, a concentra-
tion that was experimentally determined to be effective at
degrading JAK2 protein and blocking STAT3 phosphoryl-
ation in MDA-MB-231 cells. The STAT5 inhibitor was used
to treat cells at a 50 μM final concentration (Calbiochem),
whilePD098059 was used at 20 μM [32]. Cells were pre-
treated with 10 μg of Actinomycin D (Sigma) for 1 hr
prior to culture in the presence of PRL for 24 hr.
Plasmid constructs
The cloning of the full-length LKB1 construct from −1889/+
1109 into pGL3-Basic (Promega) and construction of the
LKB1Δ-1083 truncation reporter construct were described
previously [29]. The pRL-TK Renilla luciferase construct
was obtained from Dr. Julang Li (University of Guelph).
Mutation of the GAS site (5’-TTCCAAGAA-3’) within the
distal LKB1 promoter region at -1152 was accomplished
using the Site-Directed Mutagenesis kit (Stratagene)
and complementary mutant oligonucleotides corresponding
to the sequence 5′-CCAGCATTATCTCCAGATTagtttAA
GTTGGGGTGTGAGCCAG-3′ (the GAS site is italics;
mutated base pairs in lowercase letters). Mutations were
confirmed by bi-directional sequencing. The human PRLR
LF (1869 bp of the coding sequence, GeneBank Accession
M31661.1, GI:190361) [36] was PCR amplified from cDNA
derived from MDA-MB-231 cells using the primers PRLR-
LF-FOR (5’-ATGAAGGAAAATGTGGCATCTGC-3’) and
PRLR-LF-REV (5’-TCAGTGAAAGGAGTGTGTAAAAC
ATG-3’), and the resulting product was confirmed by
sequencing and expressed in pcDNA3.1.
Cell culture and transient transfections
All human cell lines were used in accordance with in-
stitutional biosafety guidelines. MDA-MB-231 human
breast cancer cells at low passage (less than 20 passages,
ATCC #HTB-26) were maintained in DMEM supplemented
with 10% FBS, and Chinese hamster ovary (CHO-K1) cells
(ATCC #CCL-61) were cultured in DMEM/F12 containing
5% FBS and penicillin/streptomycin. T47D cells weremaintained in RPMI-1640 with 10% FBS, in either
media containing phenol red or without phenol red.
For assays, cells were plated into 6-well tissue culture-
treated plates (Falcon) at 2.5 × 105 cells/well 24 hr prior to
manipulation. Cells were transfected using Lipofectamine
2000 (Invitrogen) as described previously [29]. To assess
viable cell proliferation, cells were counted using a haemo-
cytometer and trypan blue staining.Reporter gene assays
Luciferase activity of cell lysates was determined as
previously described [29] using the Dual Luciferase
Assay (Promega) and a Berthold luminometer. Luciferase
values were corrected for transfection efficiency by de-
termining the ratio of firefly/Renilla luciferase activity
and expressed as relative units. All data were normalized
to untreated pGL3-Basic.siRNAs
Experimentally verified siRNAs for JAK2 (Hs_JAK2_7),
STAT3 (Hs_STAT3_7), STAT5A (Hs_STAT5A_2), LKB1
(Hs_STK11_7), and a negative control (Ctrl_Control_1)
were obtained from Qiagen. Transient transfections were
carried out as described previously using Hiperfect re-
agent (Qiagen). MDA-MB-231 cells plated into 6-well
plates at 1.25 × 105 cells/well 3 hr prior to treatment
with siRNAs [26,29].Real time PCR
cDNA was prepared and quantitative real time PCR was
carried out using primers to amplify human LKB1 and
the RNA polymerase II housekeeping genes, which were
previously optimized [26]. Primers described by others
[37,38], resulting in a 200 bp product, were used to
quantify mRNA levels of the human PRLR LF. Relative
mRNA levels were calculated using the 2-[Δ][Δ]Ct method
[39], and results are presented as fold changes relative to
untreated controls.Western blotting
Total cell lysates were prepared as described previously
[26,29]. 50 μg of protein was subjected to SDS-PAGE
electrophoresis on 10% polyacrylamide gels and trans-
ferred onto PVDF membranes, which were blocked in
non-fat dry milk, incubated in 1:1000 diluted primary
antibody, followed by incubation with the appropriate
anti-rabbit IgG horseradish peroxidise (HRP) secondary
antibody (1:3000, Cell Signaling Technology). Signals
were detected using the ECL Plus Western Blotting
Detection System (Amersham Biosciences) and exposed
to film. Stripped membranes were re-probed with primary
anti-Actin antibody and anti-mouse IgG-HRP.
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Densitometric analyses of blots were performed using
Image J analysis software. Values were expressed as a
percent change over the control value and are repre-
sented as the mean ± SE of at least 3 independent exper-
iments. For total and phosphorylated proteins, values
were corrected relative to actin and relative to total
protein/actin, respectively.
Co-Immunoprecipitation
Following various treatments, cells were lysed in 1X lysis
buffer supplemented with protease inhibitors. 100 μg of
non-sonicated, cleared lysate in a final volume of 200 μl
(following a protocol provided by Cell Signaling Technology)
were incubated with 2 μl of antibody against total JAK2
overnight at 4°C with end-over-end rotation, followed by
the addition of 20 μl of protein A/G agarose (Invitrogen)
and further incubation at 4°C for 3 hr. Samples were
washed 5 times with lysis buffer prior to adding 4X
SDS-sample buffer and boiling. The signal was detected
following Western blotting with anti-JAK2 or anti-phospho-
JAK2 primary antibodies and incubation with anti-rabbit
IgG-HRP. As a negative control, normal rabbit IgG
(SC-2027; Santa Cruz Biotechnology, Inc.) was used instead
of specific antibody in one IP for each group of cells. A
positive control was included during Western blotting, re-
ferred to as input, which represented 10% of cleared lysate.
Preparation of nuclear extracts
Cells were cultured in 10-cm dishes in the absence and
presence of 100 ng/mL of PRL for 24 hr before harvest-
ing nuclear extracts using the NE-PER Cytoplasmic and
Nuclear Extraction Reagents kit (Pierce) following the
manufacturer’s protocol. Protein concentrations of nuclear
extracts were determined using a Bradford assay.
EMSA
Probe preparation and EMSAs were performed as previ-
ously described [40] using the DNA 3’ End Biotinylation
kit (Pierce) and the LightShift Chemiluminescent EMSA
kit (Pierce). EMSA probes consisted of biotinylated double-
stranded oligonucleotides. Probe sequences are listed in
Table 1, with the GAS and GASmut sequences in bold
italics. For competitor assays, 200-fold molar excess of
unlabeled, double-stranded probe, corresponding to 4




Oct1 (non-specific) AGAGGATCCATGCAAATChIP assays
ChIP assays were carried out using the ChIP-IT Express
Enzymatic kit (Active Motif ) using a dounce homogini-
zer to lyse cells. Optimal enzymatic digestion of chroma-
tin from MDA-MB-231 cells was empirically determined
to occur after 10 min, yielding sheared chromatin that
migrated between 200 and 1500 bp on an agarose gel.
Equal DNA concentrations corresponding to 1.5 μg were
applied to each set of immunoprecipitation reactions,
which included either normal rabbit IgG, STAT3, or
STAT5A antibody (sc-2027, sc-7179X, or sc-1081X, re-
spectively; Santa Cruz Biotechnology). Samples were
incubated with magnetic beads overnight at 4°C with
end-over-end rotation. After reversal of cross-links, DNA
precipitation, and clean-up, enriched DNA and input were
analyzed by quantitative real time PCR with primers span-
ning the predicted GAS site, as well as primers specific to a
region of the LKB1 promoter that does not contain a puta-
tive STAT binding motif (Table 2). The efficiency of each
primer set was tested by producing a standard curve from
two-fold dilutions of input, and the integrity of products
was verified by agarose gel electrophoresis. Fold enrichment
relative to IgG was calculated for immunoprecipitated sam-
ples, and data are presented normalized to values obtained
for the negative binding region.
Statistical analyses
Results represent the mean ± SEM of at least three
independent replicates, and were analyzed by t-test
(denoted by stars) or 1-way ANOVA with a Tukey’s
post-test (denoted by different letters) to assess statis-
tical differences between groups using GraphPad Prism
software. Results were considered significant at p <0.05.
For qualitative assays, including Western blots and EMSAs,
the results shown are representative of at least two in-
dependent experiments.
Results
LKB1 plays an important role in MDA-MB-231 human
breast cancer cells
We previously showed that LKB1 contributes to AMPK
pathway activation in human breast cancer cells [26]. In
the current study, we demonstrated that, beyond modu-
lating cellular metabolism, LKB1 may also be important
in regulating cell morphology. When cultured in DMEM




Table 2 Primers for ChIP
Probe Sequence (5’-3’) Product size
LKB1-GAS-FOR GGACCTACCGATGCCAATTA 184 bp
LKB1-GAS-REV TGGGCAATAAGAGCGAAACT
LKB1-Neg-FOR GAGGACGAAGTTGACCCTGA 208 bp
LKB1-Neg-REV CAACAAAAACCCCAAAAGGA
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and the other more rounded. Knocking down LKB1 re-
sulted in distinct morphological changes, with cells be-
coming more rounded compared to cells treated with a
non-specific negative control siRNA (Figure 1A). Cell
number or viability, which was assessed by trypan blue
exclusion, were not affected (Figure 1A). LKB1 is known to
affect cell polarity and motility, and interestingly, its knock-
down resulted in decreased expression of β-tubulin, an im-
portant component of the cytoskeleton, at the protein level,
without affecting the expression of other proteins, includ-















Figure 1 LKB1 is functionally important in MDA-MB-231 human breas
MDA-MB-231 cells results in distinct morphological changes without affect
non-specific (NS) siRNA. 10X magnification of live cells using a Leica DMIL
of LKB1 reduces β-tubulin and β-catenin protein levels without affecting thcatenin, an epithelial marker that has also been implicated
in WNT signaling, were also decreased (Figure 1B). It
appears that LKB1 regulates several important cellular
processes in human breast cancer cells, warranting fur-
ther investigation into how its expression is controlled.
MDA-MB-231 cells express the PRLR and are responsive
to PRL
Our previous work demonstrated that PRL activates
LKB1-AMPK-ACC signaling in MDA-MB-231 cells. PRL
elicits cellular responses through the PRLR, with differ-
ent receptor isoforms sharing common extracellular lig-
and binding and transmembrane domains, differing
only in their intracellular regions due to alternative spli-
cing. In humans, the known PRLR isoforms include the
LF, as well as the delta S1, intermediate, and short forms
(ΔS1, IF, SF1a and SF1b, respectively) and the PRLR
binding protein (reviewed in [10]). We verified that PRL
has the potential to directly signal through the PRLR in


















t cancer cells. (A) Knock-down of LKB1 using a specific siRNA in
ing the total number of viable cells compared to cells treated with a
microscope. (B) A representative Western blot demonstrating that loss
e expression of other proteins.
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high expression of the LF. PRLR LF mRNA was detected
in MDA-MB-231 cells (Figure 2A), consistent with reports
by others [37,38]. Its expression at the protein level wasFigure 2 PRL has the potential to directly signal to LKB1 in MDA-MB-23
breast cancer cells including MDA-MB-231 cells and 184B5 normal breast epit
cells, as assessed by quantitative real time PCR. (B) Various isoforms of the PR
MDA-MB-231 cells. The LF migrates at the expected molecular weight of 85-9
levels of the LF, and (C) is comparable to migration in CHO-K1 cells transientl
Representative Western blots of a time-course demonstrating that JAK2, STAT
100 ng/mL of PRL for 24 hr. (E) Co-immunoprecipitations (IPs) were carried ou
(WB). IPs with total JAK2 followed by WB with phospho- and total JAK2 were
of total non-IP lysate or “input” as a positive control, -: no treatment, +: treated
2 hr followed by the addition of PRL for 24 hr. (F) PRL also temporally induceassessed using the monoclonal anti-human PRLR anti-
body, which specifically recognizes the extracellular do-
main common to all known isoforms (R&D Systems, Inc.).
Differences in mRNA levels were reflected at the protein1 cells. (A) The PRLR LF is expressed at the mRNA level in representative
helial cells, while levels are close to undetectable in A549 lung cancer
LR are potentially expressed at the protein level in 184B5, MCF-7, and
0 kDa, similar to the band obtained in T47D cells, which express high
y transfected with an expression vector encoding the LF of PRLR. (D)
3, and STAT5 are phosphorylated in MDA-MB-231 cells cultured with
t using equal amounts of total cell lysates followed by Western blotting
performed on lysates from 184B5, MCF-7, and MDA-MB-231 cells. I: 10%
with 100 ng/mL of PRL for 24 hr, ++: pre-treated with 5 μM WP1066 for
d inactivation (phosphorylation) of ACC.
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(Figure 2B). Additional bands were also present, which
could either be non-specifics or other PRLR isoforms. It is
possible that breast cancer cells could also express ΔS1, IF,
SF1a, SF1b, or PRLRBP, as bands that correspond to their
expected molecular weights were detected at 70, 50, 56,
42, and 32 kDa, respectively. To confirm the functional
presence of PRLR in MDA-MB-231 cells, we compared
protein levels to exogenously introduced PRLR LF expres-
sion in CHO-K1 cells, which exhibit low levels of en-
dogenous PRLR (reviewed in [10]). Transient transfection
of CHO-K1s with a mammalian expression vector encod-
ing the full-length coding sequence of the human PRLR
LF resulted in an approximately 2-fold increase in recep-
tor levels compared to cells transfected with either empty
vector (pcDNA3.1) or PRLR-SF1b encoding a short
isoform (Figure 2C). Bands for the LF were detected at
85–90 kDa, consistent with migration of the endogenous
band present at a similar molecular weight in MDA-MB-
231 cells (Figure 2C).
We next examined potential signaling through STATs,
as these proteins are commonly activated in response to
PRL stimulation in cells that express the PRLR. A time
course revealed that PRL induces a gradual increase in
JAK2 and STAT3 phosphorylation in MDA-MB-231
cells in the presence of 100 ng/mL of PRL (Figure 2D).
Densitometric analysis revealed that at 24 hr, the presence
of PRL in the culture media increased phospho-JAK2
levels by 1.5-fold (p < 0.02) and phospho-STAT3 levels
by 2.8-fold (p < 0.01) relative to time 0 (Figure 2D). An
increase in phospho-STAT5 levels also occurred in re-
sponse to PRL in MDA-MB-231 cells, although levels were
very low. To confirm the phosphorylation of JAK2, we per-
formed an immunoprecipitation (IP) for total JAK2 on ly-
sates derived from 184B5, MCF-7, and MDA-MB-231 cells
treated without and with PRL for 24 hr, or pretreated
with WP1066, a drug that degrades total JAK2 protein,
followed by Western blotting to detect both phospho-
and total JAK2 (Figure 2E). IP of JAK2 in MDA-MB-231
cells confirmed its increased activation in the presence
of PRL. Consistent with our previous findings [26], PRL
inactivated ACC, temporally increasing its phosphorylation
by 2.8-fold at 24 hr (p < 0.02) (Figure 2F).
The LKB1 promoter is a target for PRL-mediated signaling
We have shown previously that PRL is able to up-regulate
LKB1 protein levels in MDA-MB-231 cells [26]. A sig-
nificant increase in LKB1 expression at the mRNA
level was observed in MCF-7 and MDA-MB-231 cells
following sustained PRL treatment, although no changes
were observed in 184B5 normal breast epithelial cells,
and only a very minor increase occurred in T47D cells
(Figure 3A). These changes were reflected at the protein
level (Figure 3B), and a time course in MDA-MB-231cells revealed that maximal increases in LKB1 protein levels
occurred after a 24 hr culture in the presence of PRL
(Figure 3B). We therefore examined the potential in-
volvement of PRL in regulating LKB1 expression at the
transcriptional level. As shown in Figure 3C, 100 ng/mL
of PRL significantly increased LKB1 mRNA levels by ap-
proximately 1.5-fold relative to the untreated control in
MDA-MB-231 cells (p < 0.01), consistent with results in
Figure 3A, while pretreatment with Actinomycin D com-
pletely abolished this effect. The transcriptional regulation
of LKB1 by PRL was examined further using a human
LKB1 promoter reporter construct, which included the
regulatory region spanning −1889 to +1109 cloned up-
stream of a firefly luciferase gene [29]. A time course
revealed that cotransfection of MDA-MB-231 cells
with the full-length LKB1 promoter construct signifi-
cantly increased luciferase activity by approximately
1.5-fold (p < 0.02) after a 24 hr culture in the presence
of 100 ng/mL of PRL (Figure 3D). The effect on LKB1
promoter activity was dose-dependent, with a maximal
1.6-fold stimulation obtained using 100 ng/mL of PRL
for 24 hr (p < 0.05; Figure 3E). Treatment with PRL also
increased LKB1 transcriptional activity in MDA-MB-231
cells in which LKB1 was knocked down using a specific
siRNA (Figure 3F), consistent with our previous findings
[26]. In addition to PRL, we also examined the responsive-
ness of the LKB1 promoter to IL-6, which is also able to
activate JAK/STAT signaling. Treating MDA-MB-231
cells with 25 ng/ml of recombinant human IL-6 for 24 hr
significantly increased LKB1 mRNA levels by 2.6-fold
(p < 0.001; Figure 3G), also significantly increasing pro-
moter activity by 1.7-fold (p < 0.02; Figure 3H).
Computational analysis using NSITE software (Softberry
Inc.) revealed that, in addition to several EREs that we
previously characterized in MCF-7 cells [29], the LKB1
promoter also contains a putative STAT/consensus
GAS binding site (TTCNNNGAA) at −1152 bp, as well
as a hypoxia-inducible factor 1 alpha (HIF1α), an acti-
vator protein 1 (AP-1), and two octamer-binding tran-
scription factor 1 (OCT-1) sites (Figure 4A). The distal
GAS site was of particular interest, given that PRL and
cytokine stimulation are known to involve the activa-
tion and nuclear translocation of STATs, and STAT
proteins mediate the action of cytokines at similar sites
in other systems. Most STATs bind to consensus GAS
sites, TTCNmGAA, where m = 4 for STAT6 and m = 3
for the optimal binding of all other STATs [41,42]. The
sequence of the putative GAS site present in the LKB1
promoter, when reverse complemented, was found to be
identical to both a PRL-responsive distal GAS site located
in the human cyclin D1 promoter (TTCTTGGAA) [32,33]
and a canonical STAT5 binding site (PRE) within the
β-casein promoter [30,31], differing by only one base pair
from a binding site described for STAT3 (TTCTGGGAA)





































































































































































































































































Figure 3 PRL stimulates LKB1 promoter activity in MDA-MB-231 cells. (A) PRL significantly increases LKB1 mRNA levels in MDA-MB-231 and
MCF-7 cells. (B) Upper panel: a representative Western blot depicting LKB1 protein levels in 184B5, MCF-7, MDA-MB-231, and T47D cells cultured
without and with 100 ng/mL of PRL for 24 hr. Lower panel: In MDA-MB-231 cells, LKB1 protein levels increase temporally in the presence of 100
ng/mL of PRL. (C) Pretreatment of MDA-MB-231 cells with Actinomycin D (Act D) for 1 hr abrogates PRL-mediated increases in LKB1 mRNA levels.
Cells were untreated (open bars) or cultured with (black bars) 100 ng/mL of PRL for 24 hr. (D) Cells co-transfected with pGL3-Basic (Basic) or the
full-length LKB1 reporter construct (LKB1) and pRL-TK were cultured without (open bars) or with (solid bars) 100 ng/mL of PRL for 15 min, 4 hr, or
24 hr. Lysates assayed for dual luciferase activity demonstrated a significant PRL-mediated increase at 24 hr. (E) PRL dose-dependently increased
LKB1 promoter activity. Lysates from MDA-MB-231 cells co-transfected with LKB1 and pRL-TK and cultured without or with varying concentrations
of PRL (10 to 500 ng/mL) for 24 hr were assayed for dual luciferase activity. (F) Cells treated with non-specific (open bars) or LKB1 (solid bars)
siRNA for 48 hr were transfected with luciferase vectors and cultured without or with 100 ng/mL of PRL for 24 hr. Culture of MDA-MB-231 cells
for 24 hr in the presence of 25 ng/mL of recombinant human IL-6 significantly increased (G) LKB1 mRNA levels and (H) LKB1 promoter activity in
cells transfected with luciferase vectors. Data represent the mean of at least three independent experiments (±SEM) relative to controls, with
different letters denoting significant differences between groups and a * indicating significant increases between the – and + PRL groups at
24 hr (p<0.05).





















































































































































































































































































Figure 4 Truncating a region from −1889 to −1083 or mutating a distal GAS site abrogate PRL-responsiveness of the LKB1 promoter.
(A) A diagrammatic representation of the human LKB1 promoter from -1889 to +1109 bp. A GAS consensus site (TTCCAAGAA), which may potentially
be bound by STAT proteins, is located at -1152. In addition, putative binding sites for HIF1α (-1562), AP-1 (-1233), and OCT-1 (-1183, -1165) are
indicated. The location of the LKB1Δ-1083 truncation is also shown. (B) MDA-MB-231 or (C) T47D cells were transiently co-transfected with either Basic,
LKB1, or various promoter-luciferase truncation constructs (LKB1Δ-1083, -436, +270, +696, or +923) and pRL-TK and assayed for dual luciferase activity.
(D) MDA-MB-231 cells were co-transfected with either LKB1 or LKB1Δ-1083 and pRL-TK, while (E) CHO-K1 cells were co-transfected with the PRLR LF,
in addition to the constructs listed in (D), and both cell types were cultured without (open bars) or with (solid bars) 100 ng/mL of PRL for 24 hr before
measuring dual luciferase activity. Data are presented relative to untreated controls. (F) MDA-MB-231 cells were co-transfected with LKB1, LKB1Δ-1083,
or the LKB1 promoter-luciferase construct containing a mutated GAS site (GASmut) and pRL-TK, and lysates were assayed for dual luciferase activity.
Data is presented relative to Basic. (G) Transfected cells were cultured without (open bars) or with (solid bars) 100 ng/mL of PRL for 24 hr before
measuring dual luciferase activity, which is presented relative to the –PRL group. Data represent the mean of at least three independent experiments
(±SEM). Different letters denote significant differences between groups (p<0.05), while a star (*) indicates statistically significant increases in PRL-treated
LKB1 promoter activity compared to untreated controls.
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http://www.biomedcentral.com/1471-2407/14/415[43]. Truncation analysis of the promoter region in MDA-
MB-231 cells revealed the presence of a potential silencer
element in the region spanning −1889 to −1083, as loss of
this 800 bp fragment led to a significant 2-fold increase in
promoter activity (Figure 4B), consistent with our previousfindings reported in MCF-7 cells [29] and results obtained
in T47D cells (Figure 4C). PRL-responsiveness was lost in
MDA-MB-231 cells transiently transfected with LKB1Δ-
1083, a truncated luciferase reporter construct lacking the
putative GAS site (Figure 4D). As shown in Figure 4E, in
Linher-Melville and Singh BMC Cancer 2014, 14:415 Page 10 of 19
http://www.biomedcentral.com/1471-2407/14/415CHO-K1 cells transiently co-transfected with the PRLR
LF and the full-length LKB1 luciferase construct, 100 ng/mL
of PRL significantly increased promoter activity by 1.4-fold
(p < 0.0005), which was also lost when the promoter was
truncated. The putative GAS site in the distal LKB1 pro-
moter region was mutated to assess its contribution to
the stimulatory effect of PRL on transcriptional activity
in MDA-MB-231 cells. Compared to the significant in-
crease on basal LKB1 promoter activity obtained using
LKB1Δ-1083, mutation of the GAS site had only a mild
repressive effect, a change that was not statistically sig-
nificant (Figure 4F). Importantly, the LKB1 full-length
promoter with the mutated GAS site did not respond to
PRL (Figure 4G).
STAT signaling is important for basal and PRL-mediated
activation of the LKB1 promoter
To assess the contribution of the STAT pathway in MDA-
MB-231 cells, we employed an siRNA approach. Transient
knock-down of each target with a specific siRNA was first
confirmed at the protein level compared to cells treated
with a non-specific (NS) siRNA (Figure 5A). Transfection
with JAK2 siRNA significantly up-regulated basal LKB1
promoter activity by approximately 3.8-fold relative to the
NS control (p < 0.0001), an effect similar to that obtained
using the LKB1Δ-1083 reporter construct (Figure 5B).
Although knock-down of STAT3 increased basal pro-
moter activity, the effect was not statistically significant
(p = 0.08), while STAT5A knock-down significantly in-
creased basal LKB1 promoter activity by approximately
3-fold (p < 0.05; Figure 5B). Decreasing the levels of either
STAT3 or STAT5A using an siRNA approach resembled
the effect observed with the GASmut reporter construct.
Basal increases in LKB1 transcriptional activity were largely
reflected at the protein level (Figure 5C). Knock-down
of JAK2, STAT3, or STAT5A completely abolished the
PRL-mediated induction of LKB1 promoter activity
compared to the NS siRNA (Figure 5D). In MCF-7 cells,
in which PRL treatment also increased LKB1 mRNA and
protein levels (Figure 3A and B), the LKB1 promoter was
mildly but significantly activated in response to treatment
with PRL (by approximately 1.2-fold, p < 0.001), although
not to the same level as observed in MDA-MB-231 cells
(Figure 5E). Similar to MDA-MB-231 cells, knock-down
of STAT3 in MCF-7 cells abolished PRL-responsiveness,
although no effect was observed with the STAT5A siRNA
(Figure 5E).
Pretreatment of MDA-MB-231 cells with the STAT3
pathway inhibitor WP1066 significantly abolished PRL-
mediated increases in promoter activity to levels com-
parable to the untreated control (Figure 6A). Although
the STAT5 inhibitor did not significantly alter PRL-
responsiveness compared to the untreated control, there
was a trend toward reducing transcriptional activitymediated by PRL. PD098059, a MAPK pathway inhibitor,
also completely abolished the effect of PRL (Figure 6A).
WP1066 effectively blocked STAT3 phosphorylation
induced by PRL after 24 hr, from a 2.3-fold increase to
0.54-fold (Figure 6B). Consistent with reports by others
[44], it also degraded total JAK2 protein, as well as re-
ducing the levels of total LKB1 (Figure 6B).
PRL down-regulates LKB1 promoter activity in T47D human
breast cancer cells
Because T47D cells express high endogenous levels of the
PRLR LF, but do not exhibit increases in LKB1 mRNA or
protein following treatment with PRL, we evaluated the
responsiveness of the LKB1 promoter to PRL in this
breast cancer cell line. PRL induced the expected rapid
activation of STAT5 (within 15 min, results not shown),
and T47D cells were therefore treated with PRL for 15 min
to assess the effect of knocking down JAK2, STAT3, and
STAT5A on LKB1 transcriptional activity. Interestingly,
PRL significantly down-regulated promoter activity in
the NS siRNA control group by 40% (Figure 7A). In cells in
which JAK2 or STAT3 were knocked down, PRL-induced
promoter activity increased by approximately 1.7- or 2-fold
in the presence of PRL (compare the results for NS at 0.61-
fold to J↓ at 1.04-fold and S3↓ at 1.22-fold), while knock-
down of STAT5A did not produce any significant changes
(Figure 7A). These results are distinct from those observed
using a similar siRNA approach in MDA-MB-231 or MCF-
7 cells, which express low levels of PRLR LF. As we previ-
ously showed that EREs present in the promoter region
may be important in regulating LKB1 expression in MCF-7
cells, and T47D cells are also ER-positive, we evaluated
the effect of treating T47D cells with PRL under phenol
red-free conditions. When the estrogen-like properties
conferred by phenol red were withdrawn from the culture
medium, treatment with PRL increased LKB1 promoter
activity in a manner similar to what was observed in
MDA-MB-231 cells (Figure 7B). Knock-down of STAT3
and STAT5A abolished PRL-responsiveness under these
conditions (Figure 7B). Pretreatment with WP1066 or the
STAT5 inhibitor produced results that were comparable
to those obtained using siRNAs in either media containing
phenol red or under phenol red-free culture conditions
(Figures 7C and D, respectively).
PRL induces binding of STATs to the GAS site in the distal
LKB1 promoter region
To demonstrate that nuclear proteins present in MDA-
MB-231 cells bind to the putative GAS site in the distal
LKB1 promoter, EMSAs were carried out. Gel shift ex-
periments revealed the formation of specific complexes
in the presence of the GAS probe (Figure 8A). Nuclear
extracts isolated from cells treated with PRL for 24 hr





Figure 5 JAK2, STAT3, and STAT5A differentially affect basal and PRL-stimulated LKB1 promoter activity in MDA-MB-231 cells.
MDA-MB-231 cells were transfected with non-specific siRNA (NS) or specific siRNAs targeting JAK2 (J2), STAT3 (S3), or STAT5A (S5A). (A) After 48
hr, knock-down was confirmed at the protein level by Western blotting. (B) Cells treated with siRNAs were co-transfected with Basic or LKB1 and
pRL-TK, and lysates were assayed for dual luciferase activity. Data are presented relative to Basic. (C) Changes elicited by each siRNA at the basal
transcriptional level were also assessed by examining total LKB1 protein levels. (D) Knock-down cells transfected with luciferase constructs as in
(B) were cultured without or with 100 ng/mL of PRL for 24 hr, and lysates were analyzed using the dual luciferase assay. Changes in firefly/renilla
relative to Basic are shown in the left panel, while the resulting fold changes in PRL-responsiveness are shown in the right panel (-PRL = open
bars, +PRL = solid bars). (E) MCF-7 cells were transfected with the indicated siRNAs followed by transfection with the luciferase constructs. Results
represent the mean of at least three independent experiments (±SEM). Different letters denote significant differences between the +PRL groups
(p<0.05), and a star (*) indicates statistically significant increases in PRL-treated LKB1 promoter activity (p<0.05) compared to untreated NS siRNA.
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derived from untreated cells (Figure 8A). An unlabeled
GAS probe effectively competed with formation of complex
2, while unlabeled oligonucleotides containing either a mu-
tated GAS sequence or an unrelated nonspecific probe se-
quence were unable to compete for complex formation.Pretreatment with WP1066 prior to stimulation with PRL
reduced formation of complex 2 (Figure 8B).
To definitively demonstrate that PRL increased the bind-
ing of STAT3 and/or STAT5A to the GAS site, ChIP assays
linked with quantitative real time PCR were carried out on
chromatin isolated from unstimulated and PRL-stimulated
AB
Figure 6 WP1066, STAT5 inhibitor, and PD098059 affect PRL signaling to the LKB1 promoter in MDA-MB-231 cells. (A) MDA-MB-231 cells
were co-transfected with Basic or LKB1 and pRL-TK. Cells were cultured without (-, top panel; open bars, bottom panel) or with (+, top panel; solid
bars, bottom panel) 100 ng/mL of PRL for 24 hr, and parallel groups of cells were pre-treated with WP1066, STAT5 inhibitor, or PD098059 for 2 hr
prior to adding PRL for an additional 24 hr (++, top panel). Cell lysates were assayed for dual luciferase activity. Data in the top panel is presented
relative to Basic, while the lower panel represents data normalized to the –PRL group. Results represent the mean of at least three independent
experiments (±SEM), with different letters denoting significant differences between the PRL-treated groups (p<0.05) and a star (*) indicating
statistically significant increases in PRL-treated LKB1 promoter activity (p<0.01) compared with the non-PRL-treated control. (B) A representative
Western blot and densitometric analyses showing that the STAT3 pathway inhibitor WP1066 effectively degrades total JAK2 protein, blocks
PRL-stimulated STAT3 phosphorylation, and reduces total levels of LKB1 protein.
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enrichment of STAT5A binding to the LKB1 promoter re-
gion containing the GAS site in response to PRL treatment
was significantly reduced by pretreating cells with WP1066or the STAT5 inhibitor (Figure 8C). Although not statis-
tically significant, STAT3 binding at this site was also
increased by PRL by approximately 2-fold, an effect that
was abrogated by pretreatment with WP1066 but not
AB
C D
Figure 7 Phenol red modulates PRL-responsiveness of the LKB1 promoter in T47D cells. T47D cells were co-transfected with LKB1 and
pRL-TK, followed by culture without (open bars) or with (solid bars) 100 ng/mL of PRL for 24 hr in (A) media containing phenol red or (B) phenol
red-free media. Cells in (A) and (B) were first transfected with non-specific siRNA (NS) or specific siRNAs targeting JAK2 (J2), STAT3 (S3), or STAT5A
(S5A) for 48 hr. Transfected T47D cells in (C) media with phenol red or (D) phenol red-free media were pretreated for 2 hr with WP1066 or the
STAT5 inhibitor prior to adding PRL for an additional 24 hr. Lysates were assayed for dual luciferase activity. Data represent the mean of three
independent experiments (±SEM) calculated relative to untreated controls, with different letters denoting significant differences between the
PRL-treated groups and a star (*) indicating statistically significant increases in PRL-treated LKB1 promoter activity (p<0.05) compared with
untreated controls.
Linher-Melville and Singh BMC Cancer 2014, 14:415 Page 13 of 19
http://www.biomedcentral.com/1471-2407/14/415the STAT5 inhibitor (Figure 8C). Gel eletrophoresis of
the real-time PCR reactions visually showed that, com-
pared to IgG, STAT3 and STAT5A binding was higher
following PRL treatment (Figure 8D).
Discussion
Current research suggests that loss of LKB1, an important
multi-tasking protein, is linked with changes in cell polarity
and cytoskeletal rearrangements, and that these changes
may drive tumor growth when the cellular metabolicbalance is disrupted in response to energetically unfavor-
able conditions. We previously showed that activation of
the AMPK pathway involves LKB1 in human breast cancer
cells. In the current investigation, we suggest that LKB1
may also control specific structural changes that could
potentially be important during disease progression, as
its knockdown in MDA-MB-231 cells produced marked
morphological changes, warranting further investigation
into the mechanisms that control its expression in breast




Figure 8 PRL induces binding of STAT3 and STAT5A to the GAS site in the distal LKB1 promoter region. (A) Nuclear extracts from
MDA-MB-231 cells cultured for 24 hr without or with 100 ng/mL of PRL were added to binding reactions with a labeled LKB1 promoter probe
spanning the GAS site and subjected to EMSA. Arrows indicated the formation of two specific complexes (SC1 and SC2), with PRL enhancing
SC2 and decreasing SC1 (lanes 2 and 3). Nuclear extracts were pretreated with unlabeled GAS probe ranging from 1-4 pmol (lanes 4, 5, 6),
unlabeled mutated GAS probe (GASmut) (lane 7), or unlabeled nonspecific (NS) probe (lane 9). (B) Nuclear extracts from cells pretreated
with WP1066 for 2 hr prior to adding PRL for 24 hr were incubated with labeled probe, demonstrating reduced SC2 formation. Arrows
indicate free probe (F) and a non-specific (NS) from probe alone. EMSAs in (A) and (B) represent results from at least two independent experiments.
(C) and (D) represent ChIPs with anti-STAT3 and anti-STAT5A antibodies. A region spanning the putative GAS site in the distal LKB1 promoter region
was PCR amplified from input, antibody-, or normal rabbit IgG-immunoprecipitated chromatin from untreated (-PRL) or treated (+100 ng/mL of PRL for
24 hr) MDA-MB-231 cells. (C) ChIP-quantitative real-time PCR validated the effects of PRL on STAT binding to the GAS site in the LKB1 promoter. STAT3
binding was reduced by WP1066, and PRL-enriched STAT5A binding was reduced by WP1066 and the STAT5 inhibitor. Results are expressed as fold
enrichment relative to IgG normalized to a negative binding region. Different letters denote significant differences between treatment groups (p<0.05),
representing results from two independent experiments. (D) ChIP PCR products analyzed by agarose gel electrophoresis confirmed the presence of
one specific band at 184 bp enriched in the +PRL group.
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in MDA-MB-231 cells altered their morphology, indi-
cated by loss of the typical spindle shape, with cells be-
coming rounded [45]. LKB1 has been linked with theWNT pathway (reviewed in [46]), and assays carried
out in Xenopus and mammalian cells demonstrate that
LKB1 upregulates β-catenin only in the presence of WNT
[47]. Furthermore, in Peutz-Jeghers syndrome polyps, the
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related [48]. We report that knock-down of LKB1 in
MDA-MB-231 cells is associated with decreased levels
of β-catenin and β-tubulin, a key component of micro-
tubules. In mice, knockdown of Lkb1 results in disintegra-
tion of neurofilaments and microtubules in the spinal cord,
with decreased staining for β-tubulin III [49], and loss
of pancreatic Lkb1 deregulates AMPK and protein fam-
ily members that establish tight junctions and mediate
tubulin dynamics, leading to acinar polarity defects and
cystic neoplasms [50]. Furthermore, in another study
identifying LKB1 as a critical mediator in the WNT path-
way, microtubules were affected in Lkb1 knockout cells
undergoing excessive cilia disassembly [51]. Loss of polar-
ity and cytoskeletal rearrangements are generally associ-
ated with tumor progression, and these changes are linked
with the epithelial-to-mesenchymal transition. Altered
levels of LKB1 could change expression of β-catenin and
other key markers of this process, thereby driving asym-
metric cell division and shifting the balance between self-
renewal, differentiation, and de-differentiation [52]. Others
have shown that by activating JAK2 in MDA-MB-231
cells, PRL regulates the morphogenic program, suppress-
ing metastatic potential and acting as an invasion suppres-
sor [53], and long-term administration of PRL to cultured
neonatal rat pancreatic islet cells increases β-catenin levels
[54]. While the molecular basis underlying how LKB1 af-
fects cell polarity and cytoskeletal arrangements in breast
cancer cells remains to be determined, our study focused
on gaining a better understanding of how LKB1 expres-
sion is regulated, which may vary depending on the mo-
lecular signature of different breast cancer cells.
We previously reported that LKB1 protein levels in-
crease in response to PRL in MDA-MB-231 cells [26],
suggesting that LKB1 expression could be transcription-
ally regulated. While variable levels of LKB1 have been
reported in MDA-MB-231 cells [55,56], a recent study
corroborates our finding that LKB1 is present and func-
tional in this particular human breast cancer cell line
[57]. These cells are commonly used in experimental
models to represent aggressive, basal-like, triple-negative
human breast cancer cells. To determine whether PRL
could directly alter LKB1 expression, we examined the
PRLR status in MDA-MB-231 cells, as well as several
other cell lines. Seventy to 95% of human breast cancers
express the PRLR [58,59]. It has been suggested that,
compared to MCF-7 cells, the PRLR is not expressed in
MDA-MB-231 cells due to DNA hypermethylation of its
promoter region [60], although expression at the protein
level was not assessed. Others have shown that several
isoforms of PRLR, including the LF, SF1a, and SF1b, are
expressed at the protein level in both MCF-7 and MDA-
MB-231 xenografts [37]. Furthermore, changes in the
expression of several different homo- and heterodimericPRLR pairs consisting of the long and short forms were
observed in MDA-MB-231 cells over the course of pro-
longed PRL stimulation [61]. Activation of JAK2 and sig-
naling to STATs has been reported for the LF, as well as
several other splice variants (reviewed in [62]). In the
current investigation, we show that PRLR LF, and poten-
tially several other isoforms that also support signaling
through STATs, are expressed in MDA-MB-231 cells,
and that JAK2 and STAT3, as well as STAT5, are acti-
vated following sustained PRL treatment.
PRL has been shown to up-regulate the transcription
of numerous target genes by promoting signaling to
GAS sites that are bound by STAT proteins, including
cyclin D1 [32,33] and β-casein [30,31]. The activity of a
LKB1 promoter-luciferase reporter construct was signifi-
cantly enhanced by PRL in MDA-MB-231 cells, an effect
that was lost upon truncation of the distal promoter re-
gion containing a putative GAS/STAT binding site. This
GAS site was confirmed to be important in mediating
transcriptional activity, and JAK2, STAT3, and STAT5A
were shown to be required for PRL to stimulate the
LKB1 promoter in MDA-MB-231 cells. Furthermore,
in vivo binding of STAT3 and STAT5A to the GAS site
was enriched in MDA-MB-231 cells following treatment
with PRL. The contribution of STAT5A in regulating
PRL-responsiveness was unexpected, given that STAT5
phosphorylation was very low in this cell line. Its im-
portance was, however, definitive, as both chemical and
siRNA-mediated inhibition blocked PRL-responsiveness
of the LKB1 promoter. The effect of PRL on STAT acti-
vation was not observed until 24 hours post-stimulation.
A similar time frame has been described for assessing
STAT5A-mediated reporter gene activity of other pro-
moters in breast cancer cells stimulated with a similar
concentration of PRL [63]. However, it is possible that
sustained treatment with PRL activates other proteins
first, particularly given the low levels of PRLR LF in
MDA-MB-231 cells. These proteins could potentially in-
duce the synthesis of factors that in turn activate JAK/
STAT signaling, thereby indirectly contributing to LKB1
transcriptional activity. It is possible, for example, that
the action of phosphatases is inhibited, the effects of
which would accumulate over time. Indeed, others have
shown that levels of the JAK2 phosphatase, PTP1B, are
inversely correlated with nuclear levels of phosphorylated
STAT5A and B in human breast cancer and that PTP1B
suppressed the levels of PRL-induced phosphorylated
STAT5A [64]. The lack of STAT5 phosphorylation in the
presence of continued total STAT5 protein expression
in clinical breast cancer samples suggests that tyrosine
phosphatases are important regulators, and Johnson
et al. (2010) show that PTP1B protein levels may be
higher in MCF-7 and MDA-MB-231 cells compared to
T47D cells [64]. Our results indicate that total levels of
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and changes in PTP1B levels may therefore be of rele-
vance to our study. We aim to investigate the mechan-
ism(s) underlying the delayed response reported in the
current investigation in future studies. Nevertheless, it is
clear that STAT3 and STAT5 both play a role in regulating
LKB1, and that PRL and other cytokines known to induce
STAT signaling, such as IL-6, modulate its expression in
a cell type-dependent manner. Interestingly, PRL has
been shown to induce the production of IL-6 in murine
dendritic cells in vitro and in vivo [65], and MDA-MB-231
cells have been shown to secrete IL-6 in vitro [66]. It is
therefore possible that the longer time frame required for
PRL to activate JAK/STAT3 and elicit its effect on LKB1
in MDA-MB-231 cells may require up-regulated produc-
tion of IL-6, which, via signaling through the IL-6 receptor
composed of IL6Rα and GP130 heterodimers, then stimu-
lates the LKB1 promoter through autocrine activation
of the JAK/STAT pathway. STAT5 is phosphorylated in
endothelial cells treated with IL-3, which suggests an
involvement in angiogenesis and cell motility [67], and
it is therefore also possible that IL-3 may play a role in
breast cancer cells. It will be of considerable interest to
explore whether PRL induces IL-6 or IL-3 expression in
MDA-MB-231 cells, and whether depleting these cytokines
from conditioned media or blocking their receptors affects
LKB1 expression.
Truncation of the region spanning −1889 to −1083
dramatically increased basal transcriptional activity, while
mutation of the GAS site only mildly lifted basal repression,
suggesting that (an)other site(s) within these 800 base
pairs likely confers the major inhibitory effect. Knock-
down of STAT3 and STAT5, similar to GAS mutation,
did not lift basal repression to the same extent as promoter
truncation. In contrast, knockdown of JAK2 produced
a dramatic effect similar to truncation, suggesting that
broader JAK2-mediated signaling contributes to basal
transcriptional repression at the LKB1 locus. While
knockdown of one STAT family member could poten-
tially lead to a compensatory action by other family
members, it is also possible that STATs, in particular
STAT5A, are not repressive on their own, but interact
with or enhance the action of (an)other repressor(s) in
the absence of PRL. For example, in the case of cyclin
D1, PRL stimulation decreased constitutive binding of
OCT-1 to a specific site in the promoter region, thereby
lifting basal transcriptional repression, and PRL-mediated
cyclin D1 promoter activity increased in response to
JAK2/STAT5 signaling involving an adjacent GAS site
[33]. Interestingly, we identified two putative OCT-1
sites in close proximity to the GAS site within the dis-
tal LKB1 promoter, and this potential mechanism of
regulating basal LKB1 transcription will be explored in
future studies, particularly given that EMSAs indicatedthe presence of a specific complex that is reduced when
cells are treated with PRL.
PRL may potentially promote synergism or induce an-
tagonism between STATs and other signaling compo-
nents. In particular, contributions through the MAPK
pathway cannot be discounted, given that a putative AP-1
site also maps to the distal LKB1 promoter region. PRL
has been shown, in various cell types, to activate JNK, p38
MAPK, and ERK1/2, thereby inducing DNA binding at
AP-1 sites (reviewed in [32]), and PRL RAS-dependently
modifies the composition and activity of complexes at a
distal AP-1 site in the cyclin D1 promoter [68]. In addition
to JAK-mediated signaling, activation of the RAS-MAPK
pathway leads to the specific phosphorylation of a serine
near the C-terminus of most STATs, and, while not re-
quired for STAT activity, this change may enhance
STAT-mediated transcriptional activation [69]. We found
that PD098059, a specific MEK1/2 inhibitor, repressed
both basal and PRL-stimulated LKB1 promoter activity. In
addition, a putative early growth response 1 (EGR-1) bind-
ing site is also present in the LKB1 promoter, and it has
been shown that PRL stimulates expression of vascular
endothelial growth factor (VEGF) via Egr-1 in a JAK2 and
MAPK-dependent manner in murine mammary epithelial
cells [70]. Another interesting putative site mapping to the
distal LKB1 promoter is a HIF1α binding motif. HIF1α,
together with STAT3, has been implicated in transcrip-
tionally regulating VEGF expression via SRC in pancreatic
and prostrate carcinomas [71], suppression of HIF1α
and STAT3 is associated with anti-angiogenic activity in
hypoxic prostate cancer cells [72], and PRL increases
VEGF expression in bovine mammary cells [73]. Of note,
LKB1 is required for angiogenesis in endothelial cells [74],
and it is therefore possible that STATs and HIF1α together
control the transcriptional activity of LKB1 in breast can-
cer cells under certain conditions.
Similar to MDA-MB-231 cells, truncating the distal
LKB1 promoter region containing the putative GAS site
in T47D cells increased basal transcriptional activity.
In the presence of phenol red, which has estrogenic
properties [75], PRL down-regulated LKB1 promoter
activity in T47D cells, reciprocal to its action in MDA-
MB-231 cells. Blocking signaling through STAT3, but
not STAT5A, reversed this effect, as did culture of T47D
cells in phenol red-free conditions. In the absence of
phenol red, LKB1 promoter activity in response to PRL
was also affected by STAT3. These findings suggest
that up-regulation of LKB1 transcriptional activity by
PRL is cell type-dependent, and may be influenced by
estrogen, as well as STAT3, in ER-positive breast can-
cer cells. PRL increases ERα expression in the ovary
[76], and this could potentially be a mechanism that
down-regulates LKB1 transcriptional activity in T47D
cells in our study. Nuclear receptors, including ER, are
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cells [77]. Activation of STAT3 by IL-6 and subsequent
changes in target gene expression are suppressed by
17β-estradiol in MCF-7 cells, an effect attributed to the
direct interaction between ER and STAT3 that prevents
the DNA binding activity of STAT3 [78]. Consistent
with the findings in T47D cells reported here, we and
others have previously shown that LKB1 expression may
be transcriptionally altered by 17β-estradiol in MCF-7
cells [29,79], and while PRL does increase LKB1 promoter
activity in MCF-7 cells, the effect is significantly blunted
compared to MDA-MB-231 cells. There appears to be a
mechanistic relationship between PRL, ERα, and STAT3
in regulating LKB1 expression, the details of which remain
to be determined.
Cancer cells commonly develop resistance to therapies
over the course of treatment, and it is therefore advan-
tageous to simultaneously target several signaling pathways
to provide effective therapeutic intervention. Recently,
it has been shown that methylsulfonylmethane (MSM), a
natural compound without any known toxicities, effectively
inhibits the STAT3/VEGF and STAT5B/insulin-like growth
factor receptor (IGF-1R) pathways in human breast cancer
cells [80]. A proposed mechanism driving MSM action
in MDA-MB-231 cells is its prevention of STAT binding
to sites within target gene promoters [80]. We have not
examined the contribution of STAT5B in our study, al-
though it has been suggested that the balance between
STAT5A and B expression may be important in breast
cancer progression [81]. A recent report has suggested
therapeutically targeting phosphoinositide 3 kinase (PI3K)/
mTOR signaling in conjunction with suppression of JAK2/
STAT5 in certain triple-negative breast cancers [82]. Treat-
ment of triple-negative breast tumors with PI3K inhibitors
resulted in upregulation of the JAK2/STAT5 pathway,
leading to increased rates of metastasis, but when mice
were treated with drugs that blocked both PI3K and
JAK2/STAT5, tumor cells proliferated more slowly and
metastasized less readily, and the survival rate of the
animals increased [82]. Activated Stat5 has also been shown
to increase metastases of prostate cancer cells in nude mice,
promoting migration and invasion, also inducing rearrange-
ments of the microtubule network [83]. The importance of
targeting more than one pathway, or more than one STAT
protein, is underscored by the finding that STAT3 sup-
presses the transcription of proapoptotic genes in breast
cancer cells [84]. Feedback may also play a role, as loss of
STAT5A using SRC inhibitors facilitates the recovery of
STAT3-mediated signaling, thereby improving cell survival
in head and neck squamous carcinomas [85].
Conclusions
Understanding how PRL and other extracellular stimuli
signal to key sites in the LKB1 promoter will provideimportant insight into the cellular responses that change
during breast cancer progression. Other factors of interest
are cytokines, particularly IL-6, which plays a role in epi-
thelial tumors and is linked with differential STAT3 sig-
naling [86]. A mechanistic approach is relevant, given that
LKB1 acts either as an inducer or suppressor of apoptosis
in a cell-type dependent manner that is linked with the
severity of energy stress [23-25], and activation of the
LKB1-AMPK pathway decreases ATP-consuming pro-
cesses while increasing ATP production, which fits well
with the energy-compromised status of aggressive can-
cer cells. Upregulation of LKB1 may provide a means
for cancer cells to survive under energetically unfavor-
able conditions, and hormones/cytokines may differen-
tially alter their metastatic potential due to cytoskeletal
changes linked to LKB1. It is becoming apparent that
breast cancer therapies need to be “tailored” to the in-
dividual patient in a manner dependent on the unique
characteristics of the originating cancer cells. Examin-
ing the contribution of STAT proteins in regulating
key cellular proteins like LKB1, and their relationship
with different levels of hormone-responsiveness, is an
integral component of this process.
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